Management of Hypertrophic Obstructive Cardiomyopathy (HOCM)

Initial Pharmacologic Management Algorithm

Disopyramide is an alternative third-line agent when beta-blockers and calcium channel blockers fail, according to the American College of Cardiology 1
Diuretics should be used cautiously at low doses for congestive symptoms, as aggressive diuresis can worsen LVOT obstruction by decreasing preload, as recommended by the American College of Cardiology 1
Diuretics and vasodilators should be avoided in symptomatic patients with LVOT obstruction, though they can be used in asymptomatic patients, according to the American College of Cardiology 1

Septal Reduction Therapy (SRT)

SRT is recommended for patients with obstructive HCM who remain symptomatic despite guideline-directed medical therapy, as stated by the American College of Cardiology 1
Eligibility criteria for SRT include severe dyspnea or chest pain attributable to LVOTO that interferes with everyday activity despite optimal medical therapy, according to the American College of Cardiology 1
Dynamic LVOT gradient at rest or with physiologic provocation with peak gradient ≥50 mmHg is a criterion for SRT, as recommended by the American College of Cardiology 1
Surgical myectomy is the preferred SRT when performed by experienced operators at comprehensive HCM centers, achieving >90% relief of obstruction with perioperative mortality <1% in most centers, according to the American College of Cardiology 1
Mandatory for patients requiring concomitant cardiac surgery, as stated by the American College of Cardiology 1
Earlier myectomy may be reasonable in presence of severe progressive pulmonary hypertension attributable to LVOTO or associated MR, according to the American College of Cardiology 1
Left atrial enlargement with ≥1 episodes of symptomatic atrial fibrillation is a consideration for earlier myectomy, as recommended by the American College of Cardiology 1
Poor functional capacity attributable to LVOTO on treadmill testing is a factor in deciding earlier myectomy, according to the American College of Cardiology 1
Children and young adults with very high resting LVOT gradients (>100 mmHg) may be considered for earlier myectomy, as stated by the American College of Cardiology 1
Alcohol septal ablation is recommended for adult patients who remain severely symptomatic despite GDMT when surgery is contraindicated or risk is unacceptable due to serious comorbidities or advanced age, according to the American College of Cardiology 1
SRT may be considered as an alternative to escalation of medical therapy after shared decision-making including risks and benefits of all treatment options, as recommended by the American College of Cardiology 1
SRT is not recommended for asymptomatic patients with normal exercise capacity, according to the American College of Cardiology 1

Management of Acute Hypotension in HOCM

Acute hypotension in obstructive HCM is a medical urgency requiring immediate intervention, as stated by the American College of Cardiology 1
Treatment priorities include maximizing preload and afterload while avoiding increases in contractility or heart rate, according to the American College of Cardiology 1
Phenylephrine is the preferred agent to reverse acute hypotension, as recommended by the American College of Cardiology 1
Beta-blockade can be useful in combination with vasoconstrictors to dampen contractility and improve preload by prolonging diastolic filling, according to the American College of Cardiology 1

Management of Comorbidities

Beta-blockers and non-dihydropyridine calcium channel blockers are preferred antihypertensive agents in obstructive HCM, as recommended by the American College of Cardiology 2
Lifestyle modifications and medical therapy for hypertension are recommended, according to the American College of Cardiology 2
Counseling and comprehensive lifestyle interventions are recommended for achieving and maintaining weight loss, potentially lowering risk of developing LVOTO, heart failure, and atrial fibrillation, as stated by the American College of Cardiology 2
Obesity is present in >70% of adult HCM patients and is independently associated with increased burden of LVH, more symptoms, and worse outcomes, according to the American College of Cardiology 2
Assessment for symptoms of sleep-disordered breathing is recommended, with referral to sleep medicine specialist if present, as recommended by the American College of Cardiology 2
Sleep-disordered breathing affects 55-70% of HCM patients and is associated with greater symptom burden, reduced exercise capacity, and higher prevalence of atrial fibrillation and NSVT, according to the American College of Cardiology 2

Hypertrophic Cardiomyopathy Management

Introduction to Harmful Agents

The American College of Cardiology recommends avoiding amlodipine in HCM patients with resting or provocable left ventricular outflow tract obstruction due to its potential to worsen symptoms 3, 4
The American College of Cardiology states that terazosin is contraindicated in HCM patients as it causes vasodilation that can worsen LVOT obstruction and precipitate hemodynamic collapse 3

Calcium Channel Blocker Use in HCM

The American College of Cardiology guidelines explicitly state that nifedipine and other dihydropyridine calcium channel blockers are potentially harmful for treating symptoms in HCM patients with resting or provocable LVOT obstruction, classified as a Class III: Harm recommendation 3, 4
The American Heart Association and American College of Cardiology recommend verapamil and diltiazem (non-dihydropyridines) as Class I recommended alternatives when beta-blockers fail or are contraindicated in HCM patients 3, 4, 5, 6
Verapamil can be titrated up to 480 mg/day for symptom control in both obstructive and nonobstructive HCM, according to the American College of Cardiology 3, 4

Evidence-Based Treatment Algorithm

The American College of Cardiology recommends beta-blockers as the primary first-line agents for symptomatic HCM (both obstructive and nonobstructive), titrated to resting heart rate <60-65 bpm 3, 5, 6
The American College of Cardiology suggests verapamil or diltiazem (non-dihydropyridines only) as second-line therapy when beta-blockers are ineffective, not tolerated, or contraindicated in HCM patients 3, 4, 5, 6
Mavacamten (cardiac myosin inhibitor) is recommended for adults with persistent NYHA class II-III symptoms despite beta-blockers or calcium channel blockers, as a Class I recommendation by the American College of Cardiology 7

Management of Hypertension in HCM Patients

The American College of Cardiology prefers beta-blockers and non-dihydropyridine calcium channel blockers in HCM patients with obstructive physiology who require antihypertensive therapy 8
ACE inhibitors and ARBs have uncertain benefit and are potentially harmful in patients with resting or provocable LVOT obstruction, according to the American College of Cardiology 3, 4

Common Pitfalls to Avoid

The American College of Cardiology advises against prescribing dihydropyridine calcium channel blockers (amlodipine, nifedipine, felodipine) for HCM patients, especially those with obstruction 3, 4
The American College of Cardiology recommends avoiding all vasodilators, including alpha-blockers (terazosin, doxazosin), nitrates, and hydralazine, in obstructive HCM 3
In acute hypotension with obstructive HCM, the American College of Cardiology suggests using phenylephrine (pure vasoconstrictor), never vasodilators or inotropes like dopamine or dobutamine 3, 4

Metoprolol Formulation for Hypertrophic Obstructive Cardiomyopathy

Guideline Recommendations on Beta-Blocker Selection

The American Heart Association, American College of Cardiology, and other societies recommend "nonvasodilating beta blockers" as first-line therapy for symptomatic obstructive HCM, titrated to effectiveness or maximally tolerated doses, but does not distinguish between metoprolol formulations 9
Neither the 2024 HCM guideline nor the 2018 hypertension guideline provides a Class I recommendation favoring one metoprolol formulation over the other specifically for HOCM 10, 9

Key Distinction: Heart Failure vs. HOCM Evidence

The heart failure literature clearly distinguishes between formulations—metoprolol succinate (extended-release) demonstrated mortality reduction in heart failure trials, while metoprolol tartrate (immediate-release) did not show the same benefit 11, 12
In the COMET trial comparing carvedilol to metoprolol tartrate in heart failure, carvedilol showed superior mortality reduction, but this trial used metoprolol tartrate at doses and formulations different from the metoprolol succinate used in MERIT-HF 11, 12

Practical Dosing Considerations

Metoprolol tartrate: Typically dosed 100-200 mg divided twice daily for HOCM, as indicated in the 2018 hypertension guideline table 10
Metoprolol succinate: Typically dosed 50-200 mg once daily, providing equivalent beta-blockade with simplified dosing 10
Both formulations should be titrated gradually to achieve target heart rate of 60-65 bpm at rest, monitoring for symptomatic improvement in dyspnea and chest pain 9

Common Pitfalls to Avoid

Do not abruptly discontinue either metoprolol formulation, as this can precipitate rebound tachycardia and worsening symptoms in HOCM patients 10
Avoid using metoprolol in combination with non-dihydropyridine calcium channel blockers (verapamil, diltiazem) due to increased risk of bradycardia and heart block 10
Do not confuse the heart failure evidence favoring metoprolol succinate with a specific requirement for HOCM—the guideline-directed medical therapy for HOCM does not mandate one formulation over the other 9
If beta-blockers prove ineffective or poorly tolerated, substitute with non-dihydropyridine calcium channel blockers (verapamil or diltiazem) rather than switching between metoprolol formulations 9

Algorithm for Beta-Blocker Selection in HOCM

Start with either metoprolol formulation based on patient preference for dosing frequency and insurance coverage, as both are acceptable first-line options 9
If inadequate response after reaching maximally tolerated beta-blocker doses, consider adding mavacamten (cardiac myosin inhibitor), disopyramide, or referring for septal reduction therapy rather than switching metoprolol formulations 9

HOCM Management Guidelines

Introduction to HOCM Treatment

The American Heart Association and American College of Cardiology recommend that flecainide is not used in the management of hypertrophic obstructive cardiomyopathy, as it does not appear in current evidence-based treatment algorithms for this condition 13, 14, 15

Pharmacologic Treatment Options

Mavacamten, a cardiac myosin inhibitor, is a Class I recommendation for adults with persistent NYHA class II-III symptoms despite beta-blockers or calcium channel blockers, according to the American College of Cardiology 14, 15
Disopyramide, a Class IA antiarrhythmic with strong negative inotropic effects, is recommended for HOCM symptom management, as stated by the American Heart Association 13, 14

Antiarrhythmic Agents in HOCM

Class IC antiarrhythmics like flecainide are not part of the established pharmacologic management strategy for LVOT obstruction, as stated by the American College of Cardiology and American Heart Association 13, 14, 15

Management of Hypertrophic Obstructive Cardiomyopathy (HOCM)

Initial Pharmacologic Management Algorithm

The American Heart Association recommends beta-blockers as the first-line pharmacologic therapy for all symptomatic HOCM patients, titrated to a resting heart rate of 60-65 bpm, with non-dihydropyridine calcium channel blockers as second-line when beta-blockers fail or are contraindicated 16
Beta-blockers reduce left ventricular outflow tract gradients through negative inotropic effects and prolonged diastolic filling time, alleviating dyspnea, chest pain, and improving quality of life in patients with HOCM 17
The American College of Cardiology recommends verapamil or diltiazem as Class I alternatives when beta-blockers are ineffective, not tolerated, or contraindicated in patients with HOCM 16, 17

Septal Reduction Therapy (SRT)

The American Heart Association recommends SRT for patients with obstructive HCM who remain severely symptomatic despite guideline-directed medical therapy 16
Surgical myectomy is the preferred SRT when performed by experienced operators at comprehensive HCM centers, achieving >90% relief of obstruction with perioperative mortality <1% in patients with HOCM 16
Alcohol septal ablation is recommended for adult patients who remain severely symptomatic despite guideline-directed medical therapy when surgery is contraindicated or risk is unacceptable due to serious comorbidities or advanced age 16

Atrial Fibrillation Management

The American Heart Association recommends oral anticoagulation with direct-acting oral anticoagulants as the default treatment option for patients with HCM and persistent or paroxysmal atrial fibrillation, irrespective of CHA₂DS₂-VASc score 16
Patients with HCM and atrial fibrillation have a sufficiently increased risk of stroke that anticoagulation is recommended independent of traditional risk stratification tools 16

Sudden Cardiac Death Risk Stratification

The American College of Cardiology recommends assessing a patient's risk for sudden cardiac death as an important component of management, integrating established risk markers with tools to estimate individual risk score in patients with HOCM 16
Risk stratification should incorporate the patient's personal level of risk tolerance and specific treatment goals to facilitate shared decision-making regarding implantable cardioverter-defibrillator placement in patients with HOCM 16

Family Screening and Genetic Counseling

The American Heart Association recommends careful ascertainment of family history, counseling patients about genetic transmission, and options for genetic testing as cornerstones of care for patients with HOCM 16
Screening first-degree family members using genetic testing, serial imaging, or electrocardiographic surveillance should begin at any age based on patient and family history in patients with HOCM 16

Exercise and Activity Recommendations

The American College of Cardiology recommends avoidance of particularly strenuous activity or competitive athletics for patients with HCM 17
Exercise stress testing is particularly helpful in determining overall exercise tolerance and for detecting latent exercise-provoked LVOT obstruction in patients with HOCM 16

Management of Hypertrophic Obstructive Cardiomyopathy (HOCM)

Initial Pharmacologic Management Algorithm

The American College of Cardiology recommends starting all symptomatic HOCM patients on nonvasodilating beta-blockers as first-line therapy, titrated to a resting heart rate of 60-65 bpm, and immediately discontinuing any vasodilators that worsen outflow obstruction 18
Nonvasodilating beta-blockers are the Class I recommended initial treatment for all symptomatic HOCM patients, regardless of gradient severity, and should be titrated to achieve a resting heart rate of 60-65 bpm 18
Beta-blocker failure should not be declared until maximally tolerated doses are achieved with documented heart rate suppression 18

Critical Medications to AVOID in HOCM

The American College of Cardiology recommends immediately discontinuing dihydropyridine calcium channel blockers, ACE inhibitors, and ARBs in symptomatic patients with LVOT obstruction 18
High-dose diuretics are relatively contraindicated because aggressive diuresis worsens LVOT obstruction by decreasing preload, and low-dose diuretics may be cautiously considered for persistent dyspnea with clinical evidence of volume overload despite other guideline-directed medical therapy 18

Common Pitfalls to Avoid

The American College of Cardiology recommends avoiding dihydropyridine calcium channel blockers, such as amlodipine and nifedipine, for HOCM patients, as this is a Class III: Harm recommendation 18
Declaring beta-blocker failure should be avoided until maximally tolerated doses with documented heart rate suppression (<60-65 bpm) are achieved 18
Aggressive diuresis should be avoided, as this worsens LVOT obstruction by decreasing preload 18